Focus on Optimized Dosing of Ibrutinib Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Oct

Today In Oncology

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Related Videos

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Creatine

Incidence of Invasive Lobular Carcinoma Rising Faster Than Other Breast Cancers

Gaps Persist in Follow-Up Care Among Young Survivors of Breast Cancer

Ziftomenib in Relapsed or Refractory NPM1-Mutant AML

Advanced Biliary Tract Cancer Adding a Polymeric Micellar Paclitaxel to Gemcitabine Plus Cisplatin